{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:03:27Z","timestamp":1773281007935,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.msard.2025.106312","type":"journal-article","created":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T15:09:49Z","timestamp":1738508989000},"page":"106312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Can serum C3\/C4 complement ratio be used in the differential diagnosis of central nervous system demyelinating diseases?"],"prefix":"10.1016","volume":"95","author":[{"given":"Melike","family":"Cakan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bariscan","family":"Cimen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazire P\u0131nar","family":"Acar-Ozen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yildirim","family":"Sara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Karabudak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-4483","authenticated-orcid":false,"given":"Asl\u0131","family":"Tuncer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106312_bib0001","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.922590","article-title":"Seronegative Neuromyelitis Optica spectrum disorder: an unusual presentation of acute brainstem syndrome","volume":"21","author":"Alshurafa","year":"2020","journal-title":"Am. J. Case Rep."},{"issue":"11","key":"10.1016\/j.msard.2025.106312_bib0002","doi-asserted-by":"crossref","first-page":"10676","DOI":"10.18632\/aging.103286","article-title":"Modelling biological age based on plasma peptides in Han Chinese adults","volume":"12","author":"Cao","year":"2020","journal-title":"Aging (Albany. NY)"},{"key":"10.1016\/j.msard.2025.106312_bib0003","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2019.01869","article-title":"Editorial: the role of complement in health and disease","volume":"10","author":"Cedzy\u0144ski","year":"2019","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.msard.2025.106312_bib0004","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/rth2.12388","article-title":"Serum complement levels in immune thrombocytopenia: characterization and relation to clinical features","volume":"4","author":"Cheloff","year":"2020","journal-title":"Res. Pract. Thromb. Haemostasis"},{"issue":"3","key":"10.1016\/j.msard.2025.106312_bib0005","doi-asserted-by":"crossref","first-page":"J276","DOI":"10.1016\/j.jaut.2009.11.014","article-title":"The complement system in systemic autoimmune disease","volume":"34","author":"Chen","year":"2010","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.msard.2025.106312_bib0006","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10072-013-1481-y","article-title":"The complement and immunoglobulin levels in NMO patients","volume":"35","author":"Chen","year":"2014","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106312_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102979","article-title":"The complement system and human autoimmune diseases","volume":"137","author":"Coss","year":"2023","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.msard.2025.106312_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1135540","article-title":"Central nervous system demyelinating diseases: glial cells at the hub of pathology","volume":"14","author":"Coutinho Costa","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2025.106312_bib0009","first-page":"815","article-title":"Neuromyelitis Optica spectrum disorder and other non-multiple sclerosis Central nervous system inflammatory diseases","volume":"25","author":"Flanagan","year":"2019","journal-title":"Continuum (Minneap. Minn)"},{"key":"10.1016\/j.msard.2025.106312_bib0010","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2018.02664","article-title":"Age and sex-associated changes of complement activity and complement levels in a healthy Caucasian population","volume":"9","author":"Gaya da Costa","year":"2018","journal-title":"Front. Immunol."},{"issue":"11\u201312","key":"10.1016\/j.msard.2025.106312_bib0011","first-page":"137","article-title":"Determination of normal ranges for serum C3 and C4 levels in an adult Zimbabwean population","volume":"48","author":"Gomo","year":"2002","journal-title":"Cent. Afr. J. Med."},{"issue":"7","key":"10.1016\/j.msard.2025.106312_bib0012","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/1352458516669002","article-title":"Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"23","author":"Hakobyan","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106312_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102376","article-title":"Myelin oligodendrocyte glycoprotein antibody associated central nervous system demyelinating disease: a tertiary center experience from Turkey","volume":"44","author":"Inan","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106312_bib0014","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J. Neuroinflammation."},{"key":"10.1016\/j.msard.2025.106312_bib0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaut.2014.01.022","article-title":"The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review","volume":"48-49","author":"Karussis","year":"2014","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.msard.2025.106312_bib0016","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3345\/cep.2019.01305","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disorders: clinical spectrum, diagnostic evaluation, and treatment options","volume":"64","author":"Lee","year":"2021","journal-title":"Clin. Exp. Pediatr."},{"key":"10.1016\/j.msard.2025.106312_bib0017","article-title":"Plasma complement 3 and complement 4 are promising biomarkers for distinguishing NMOSD from MOGAD and are associated with the blood-brain-barrier disruption in NMOSD","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.msard.2025.106312_bib0018","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/jcp.2005.031195","article-title":"Demyelinating diseases","volume":"59","author":"Love","year":"2006","journal-title":"J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.msard.2025.106312_bib0019","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106312_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.935750","article-title":"Classical and alternate complement factor overexpression in non-obese weight matched women with polycystic ovary syndrome does not correlate with vitamin D","volume":"13","author":"Moin","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.msard.2025.106312_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.933415","article-title":"Sex bias in multiple sclerosis and neuromyelitis optica spectrum disorders: how it influences clinical course, MRI parameters and prognosis","volume":"13","author":"Nytrova","year":"2022","journal-title":"Front. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2025.106312_bib0022","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jneuroim.2014.07.001","article-title":"Complement activation in patients with neuromyelitis optica","volume":"274","author":"Nytrova","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106312_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577699","article-title":"C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD","volume":"360","author":"Pache","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.msard.2025.106312_bib0024","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12882-017-0658-7","article-title":"Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy: a retrospective study","volume":"18","author":"Pan","year":"2017","journal-title":"BMC. Nephrol."},{"issue":"3","key":"10.1016\/j.msard.2025.106312_bib0025","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12026-018-8995-6","article-title":"Serum C3\/C4 ratio is a novel predictor of renal prognosis in patients with IgA nephropathy: a retrospective study","volume":"66","author":"Pan","year":"2018","journal-title":"Immunol. Res."},{"key":"10.1016\/j.msard.2025.106312_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2019.06.035","article-title":"The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders","volume":"35","author":"Qin","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2025.106312_bib0027","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/08830185.2020.1833877","article-title":"Complement system network in cell physiology and in human diseases","volume":"40","author":"Romano","year":"2021","journal-title":"Int. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2025.106312_bib0028","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/jim-2019-001126","article-title":"CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease","volume":"68","author":"Rosenthal","year":"2020","journal-title":"J. Investig. Med."},{"issue":"6","key":"10.1016\/j.msard.2025.106312_bib0029","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/bpa.12087","article-title":"Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status","volume":"23","author":"Sato","year":"2013","journal-title":"Brain Pathol."},{"key":"10.1016\/j.msard.2025.106312_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106312_bib0031","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1212\/NXI.0000000000000257","article-title":"Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis","volume":"3","author":"Spadaro","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.msard.2025.106312_bib0032","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106312_bib0033","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106312_bib0034","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.molimm.2013.09.010","article-title":"A systematic analysis of the complement pathways in patients with neuromyelitis optica indicates alteration but no activation during remission","volume":"57","author":"Veszeli","year":"2014","journal-title":"Mol. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2025.106312_bib0035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106312_bib0036","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3389\/fimmu.2018.01438","article-title":"Aquaporin-4 autoantibodies from Neuromyelitis Optica spectrum disorder patients induce complement-independent immunopathologies in mice","volume":"9","author":"Yick","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.msard.2025.106312_bib0037","first-page":"1764","article-title":"[Prognostic Value and Threshold Effect of Serum C3, C4 in Patients with Multiple Myeloma]","volume":"32","author":"Zhang","year":"2024","journal-title":"Zhongguo Shi. Yan. Xue Ye Xue Za Zhi."},{"issue":"6","key":"10.1016\/j.msard.2025.106312_bib0038","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/CM9.0000000000000674","article-title":"Relationship between serum C3\/C4 ratio and prognosis of immunoglobulin A nephropathy based on propensity score matching","volume":"133","author":"Zhang","year":"2020","journal-title":"Chin. Med. J. (Engl)"},{"issue":"4","key":"10.1016\/j.msard.2025.106312_bib0039","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3350\/cmh.2020.0094","article-title":"Roles of the complement system in alcohol-induced liver disease","volume":"26","author":"Zhou","year":"2020","journal-title":"Clin. Mol. Hepatol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T04:48:47Z","timestamp":1741841327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825000562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":39,"alternative-id":["S2211034825000562"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106312","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can serum C3\/C4 complement ratio be used in the differential diagnosis of central nervous system demyelinating diseases?","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106312"}}